Mundipharma presented new data from a Phase 3 study of the Flutiform fluticasone/formoterol MDI for the treatment of asthma in children aged 5 to 11 at the European Respiratory Society (ERS) Annual Congress, the company and Flutiform developer Skyepharma announced. Flutiform is not currently approved for pediatric use.
The data show superiority of Flutiform compared to fluticasone monotherapy and non-inferiority compared to fluticasone/salmeterol in improvement of lung function. Tolerability was comparable between all three therapies.
Flutiform was approved in Europe for ages 12 and over in 2007. Mundipharma distributes Flutiform in Europe and a number of other countries.
Read the Mundipharma press release.
